Luna-Palencia GR, Vásquez-Moctezuma I

Idioma: Español
Referencias bibliográficas: 19
Paginas: 48-53
Archivo PDF: 198.96 Kb.

RESUMEN

El estudio de la epigenética ha permitido explicar los procesos que conducen a diferentes enfermedades como el cáncer humano, la obesidad, la diabetes y otras más. Lo que ha entusiasmado a los investigadores de esta área es el hecho de que los cambios epigenéticos sobre el genoma son reversibles, lo que puede tener impacto positivo en la salud humana. Aquí se describen de manera muy general los diferentes procesos que logran la regulación genética como son la metilación y desmetilación del ADN en las islas CpG, las modificaciones postraduccionales de las histonas, y los llamados micro ARN (miRNA) que cada día muestran su influencia en diferentes procesos normales y patológicos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Armstrong L. Post-translational modification of histones. In: Armstrong L ed. Epigenetics. New York; Garland Science. 2014. pp. 59-75.

2. Kyle UG, Pichard C. The Dutch Famine of 1944-1945: a pathophysiological model of long-term consequences of wasting disease. Curr Opin Clin Nutr Metab Care. 2006; 9 (4): 388-394.

3. Bogdanović O, Lister R. DNA methylation and the preservation of cell identity. Curr Opin Genet Dev. 2017; 46: 9-14.

4. Moylan CA, Murphy SK. DNA methylation basic principles. In: Tollefsbol T. eds. Medical Epigenetics. United Kingdom; Academic Press. 2016. pp. 11-29.

5. Wood AJ, Oakey RJ. Genomic imprinting in mammals: emerging themes and established theories. PLoS Gene. 2006; 2 (11): e147.

6. Barlow DP, Stöger R, Herrmann BG, Saito K, Scheweifer N. The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus. Nature. 1991; 349 (6304): 84-87.

7. Li Y, Sasaki H. Genomic imprinting in mammals: its life cycle, molecular mechanisms and reprogramming. Cell Res. 2011; 21 (3): 466-473.

8. Soubry A, Schildkraut JM, Murtha A, Wang F, Huang Z, Bernal A et al Paternal obesity is associated with IGF2 hypomethylation in newborns: results from a Newborn Epigenetics Study (NEST) cohort. BMC Med. 2013; 11 (29): 1-10.

9. Moarii M, Boeva V, Vert JP, Reyal F. Changes in correlation between promoter methylation and gene expression in cancer. BMC genomics. 2015; 16 (1): 873.

10. Ferguson AT, Vertino PM, Spitzner JR, Baylin SB, Muller MT, Davidson NE. Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-aza-2’deoxycytidine-induced cytotoxicity in human breast cancer cells. J Biol Chem. 1997; 272 (51): 32260-32266.

11. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell. 2002; 2 (6): 485-495.

12. Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res. 2006; 66 (10): 5021-5028.

13. Matsumura N, Huang Z, Mori S, Baba T, Fujii S, Konishi I et al. Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res. 2011; 21 (1): 74-82.

14. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular biology of the cell. New York: Garland Science, 2008.

15. Sananbenesi F, Fischer A. Histone deacetylases as therapeutic targets in neurodegenerative diseases. In: Tollefsbol T. eds. Medical epigenetics. London, United Kingdom; Academic Press. 2016. pp. 33-45.

16. Robey RW, Chakraborty AR, Basseville A, Luchenko V, Bahr J, Zhan Zhirong et al. Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol Pharmaceutics. 2011; 8 (6): 2021-2031.

17. Ambros V. The functions of animal microRNAs. Nature. 2004; 431 (7006): 350-355.

18. Garzon R, Marcucci G, Croce CM Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9 (10): 775-789.

19. Elliott D, Landomery M: Molecular Biology of RNA. Oxford University Press, 2016.